Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization

Bone Marrow Transplantation volume 46, pages 956–961 (2011)Cite this article

Subjects

Abstract

SCT is important in the management of multiple myeloma. In the United States, the standard of care is administration of growth factors to accelerate neutrophil recovery after SCT. The need for growth factors after transplant has not been investigated recently. We analyzed a cohort of 166 patients at our institution who underwent autologous transplant for multiple myeloma without receiving growth factors after transplant and compared them with 498 patients who received standard filgrastim beginning on posttransplant day 5. A neutrophil count of 500/μL was achieved in a median of 12.5 days in patients receiving growth factor, compared with 13.5 days in those not receiving growth factor (P<0.001). Platelet engraftment was identical (median, 14.5 days; P=0.12) in both groups, despite a lower median number of CD34+ cells infused in patients who did not receive growth factors. Incidence of nonstaphylococcal bacteremia was identical in both groups. The median hospital stay was 3.5 days shorter in the group not receiving growth factor. It is feasible and reasonable to perform autologous SCT for multiple myeloma without administering growth factors.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Barlogie B, Jagannath S, Naucke S, Mattox S, Bracy D, Crowley J et al. Long-term follow-up after high-dose therapy for high-risk multiple myeloma. Bone Marrow Transplant 1998; 21: 1101–1107.

    Article  CAS  Google Scholar 

  2. Nemunaitis J, Rabinowe SN, Singer JW, Bierman PJ, Vose JM, Freedman AS et al. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med 1991; 324: 1773–1778.

    Article  CAS  Google Scholar 

  3. Gorin NC, Coiffier B, Hayat M, Fouillard L, Kuentz M, Flesch M et al. Recombinant human granulocyte-macrophage colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation with unpurged and purged marrow in non-Hodgkin's lymphoma: a double-blind placebo-controlled trial. Blood 1992; 80: 1149–1157.

    CAS  PubMed  Google Scholar 

  4. Khwaja A, Linch DC, Goldstone AH, Chopra R, Marcus RE, Wimperis JZ et al. Recombinant human granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a British National Lymphoma Investigation double-blind, placebo-controlled trial. Br J Haematol 1992; 82: 317–323.

    Article  CAS  Google Scholar 

  5. Messner HA . Human hematopoietic progenitors in bone marrow and peripheral blood. Stem Cells 1998; 16 (Suppl 1): 93–96.

    PubMed  Google Scholar 

  6. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Center for International Blood and Marrow Research; National Marrow Donor program; European Blood Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Disease Canada; Centers for Disease Control and Prevention et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15: 1143–1238.

    Article  CAS  Google Scholar 

  7. Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187–3205.

    Article  CAS  Google Scholar 

  8. Karlin L, Darmon M, Thiery G, Ciroldi M, de Miranda S, Lefebvre A et al. Respiratory status deterioration during G-CSF-induced neutropenia recovery. Bone Marrow Transplant 2005; 36: 245–250.

    Article  CAS  Google Scholar 

  9. Rechner I, Brito-Babapulle F, Fielden J . Systemic capillary leak syndrome after granulocyte colony-stimulating factor (G-CSF). Hematol J 2003; 4: 54–56.

    Article  Google Scholar 

  10. Gonzalez-Vicent M, Ramirez M, Sevilla J, Perez A, Fernandez S, Madero L et al. Engraftment syndrome after autologous peripheral blood progenitor cell transplantation in pediatric patients: a prospective evaluation of risk factors and outcome. Bone Marrow Transplant 2004; 34: 1051–1055.

    Article  CAS  Google Scholar 

  11. Bottcher P, Flegel T, Bottcher IC, Grevel V, Oechtering G . Partial lateral corpectomy for ventral extradural thoracic spinal cord compression in a cat. J Feline Med Surg 2008; 10: 291–295.

    Article  Google Scholar 

  12. Kuendgen A, Fenk R, Bruns I, Dommach M, Schutte A, Engers R et al. Splenic rupture following administration of pegfilgrastim in a patient with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 2006; 38: 69–70.

    Article  CAS  Google Scholar 

  13. Pulsipher MA, Chitphakdithai P, Miller JP, Logan BR, King RJ, Rizzo JD et al. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. Blood 2009; 113: 3604–3611.

    Article  CAS  Google Scholar 

  14. White JM, Mufti GJ, Salisbury JR, du Vivier AW . Cutaneous manifestations of granulocyte colony-stimulating factor. Clin Exp Dermatol 2006; 31: 206–207.

    Article  CAS  Google Scholar 

  15. Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Leung N et al. Transplantation without growth factor: engraftment kinetics after stem cell transplantation for primary systemic amyloidosis (AL). Bone Marrow Transplant 2007; 40: 989–993.

    Article  CAS  Google Scholar 

  16. Burgstaler EA, Pineda AA, Winters JL . Hematopoietic progenitor cell large volume leukapheresis (LVL) on the Fenwal Amicus blood separator. J Clin Apher 2004; 19: 103–111.

    Article  Google Scholar 

  17. Mathew S, Adel N, Rice RD, Panageas K, Duck ET, Comenzo RL et al. Retrospective comparison of the effects of filgrastim and pegfilgrastim on the pace of engraftment in auto-SCT patients. Bone Marrow Transplant 2010; 45: 1522–1527.

    Article  CAS  Google Scholar 

  18. Park KU, Kim SH, Suh C, Kim S, Lee SJ, Park JS et al. Correlation of hematopoietic progenitor cell count determined by the SE-automated hematology analyzer with CD34(+) cell count by flow cytometry in leukapheresis products. Am J Hematol 2001; 67: 42–47.

    Article  CAS  Google Scholar 

  19. Chapple P, Prince HM, Quinn M, Bertoncello I, Juneja S, Wolf M et al. Peripheral blood CD34+ cell count reliably predicts autograft yield. Bone Marrow Transplant 1998; 22: 125–130.

    Article  CAS  Google Scholar 

  20. Kozlowska-Skrzypczak M, Gil L, Komarnicki M . Factors affecting neutrophil recovery after autologous bone marrow-derived stem cell transplantation in patients with acute myeloid leukemia. Transplant Proc 2009; 41: 3868–3872.

    Article  CAS  Google Scholar 

  21. Wallington-Beddoe CT, Gottlieb DJ, Garvin F, Antonenas V, Sartor MM . Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2009; 15: 1386–1393.

    Article  Google Scholar 

  22. Ojeda E, Garcia-Bustos J, Agaudo MJ, Quevedo E, Arrieta R, Jimenez V et al. Is filgrastim as useless after peripheral blood stem cell transplantation for adults as it could be for children? Blood 1999; 93: 3565–3566.

    CAS  PubMed  Google Scholar 

  23. Kawano Y, Takaue Y, Mimaya J, Horikoshi Y, Watanabe T, Abe T, The Japanese Cooperative Study Group of PBSCT et al. Marginal benefit/disadvantage of granulocyte colony-stimulating factor therapy after autologous blood stem cell transplantation in children: results of a prospective randomized trial. Blood 1998; 92: 4040–4046.

    CAS  PubMed  Google Scholar 

  24. Klaus J, Herrmann D, Breitkreutz I, Hegenbart U, Mazitschek U, Egerer G et al. Effect of CD34 cell dose on hematopoietic reconstitution and outcome in 508 patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. Eur J Haematol 2007; 78: 21–28.

    Article  Google Scholar 

  25. Jantunen E, Kuittinen T, Penttila K, Lehtonen P, Mahlamaki E, Nousiainen T . High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (⩾65 years) myeloma patients: comparison with younger patients treated on the same protocol. Bone Marrow Transplant 2006; 37: 917–922.

    Article  CAS  Google Scholar 

  26. Fenk R, Hieronimus N, Steidl U, Bruns I, Graef T, Zohren F et al. Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. Exp Hematol 2006; 34: 1296–1302.

    Article  CAS  Google Scholar 

  27. Sung L, Nathan PC, Alibhai SM, Tomlinson GA, Beyene J . Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med 2007; 147: 400–411.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Rochester, MN, USA

    M A Gertz, D A Gastineau, M Q Lacy, A Dispenzieri, S R Hayman, S K Kumar, D Dingli, W J Hogan & F K Buadi

  2. Division of Nephrology and Hypertension, Rochester, MN, USA

    N Leung

  3. Pharmacy Services Mayo Clinic, Rochester, MN, USA

    R C Wolf

Authors
  1. M A Gertz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D A Gastineau
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Q Lacy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A Dispenzieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S R Hayman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S K Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D Dingli
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. N Leung
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R C Wolf
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. W J Hogan
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. F K Buadi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M A Gertz.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gertz, M., Gastineau, D., Lacy, M. et al. SCT without growth factor in multiple myeloma: engraftment kinetics, bacteremia and hospitalization. Bone Marrow Transplant 46, 956–961 (2011). https://doi.org/10.1038/bmt.2010.233

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2010.233

Keywords

This article is cited by

Search

Advanced search

Quick links